

Express Mail Label: EV 312 158 300 US
Docket No. JAB-1680-Div3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David W. End et al.
Serial No. : Not yet Assigned Art Unit:
Filed : Herewith Examiner:
For : Method Of Use Of (Imidazol-5-YL) Methyl-2-Quinolinone
Derivatives To Inhibit Smooth Muscle Cell Proliferation

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the


Express Mail Label: EV 312 158 300 US
Docket No. JAB-1680-Div3

national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☒ Copies of each of the references listed on the attached Form PTO-1449 are not enclosed herewith since they are available in the file wrapper of parent application 09/996,147.

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Respectfully submitted,


Gabriel Lopez
Reg. No. 28,440
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: April 14, 2004

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

<i>Application Number</i>	To Be Assigned
<i>Filing Date</i>	To Be Assigned
<i>First Named Inventor</i>	David W. End
<i>Group Art Unit</i>	To Be Assigned
<i>Examiner Name</i>	To Be Assigned
<i>Attorney Docket Number</i>	JAB-1680-Div3

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		4,565,740		Golander et al	01/21/1986	
		5,049,403		Larm et al	09/17/1991	
		5,213,898	A	Larm et al	05/25/1993	
		5,356,433	A	Rowland et al	10/18/1994	
		5,607,475	A	Cahalan et al	03/04/1997	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
		JP	7112930		Kyowa Hakko Kogyo Co. Ltd	05/02/1995/		
		WO	96/32907	A1	Schneider Inc.	10/24/1996		
		WO	97/21701	A1	Janssen Pharmaceutica, N.V.	06/19/1997		
		WO	98/55124	A1	Janssen Pharmaceutica, N.V.	12/10/1998		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2	<i>Application Number</i>	To Be Assigned
	<i>Filing Date</i>	To Be Assigned
	<i>First Named Inventor</i>	David W. End
	<i>Group Art Unit</i>	JAB-1680-Div1
	<i>Examiner Name</i>	To Be Assigned
	<i>Attorney Docket Number</i>	JAB 1680 Div3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BUCKWALD, A.B., et al.; "Inhibition of Neointimal Proliferation After Coronary Angioplasty by Low-Molecular-Weight Heparin (Clivarine) and Polyethyleneglycol-Hirudin," <u>Journal of Cardiovascular Pharmacology</u> , 1996, 28:481-487	
		INDOLFI, C., et al., "Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo," <u>Nature Medicine</u> , 1995, 1(6):541:545	
		IRANI, K., et al., "Ras Protein Regulate Multiple Mitogenic Pathways in A10 Vascular Smooth Muscle Cells," <u>Biochemical and Biophysical Research Comm.</u> , 1994 202(3):1252-1258	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<p align="center">SUBMISSION UNDER MPEP 609 D</p> <p align="center">Page 1 of 1</p>	<i>Application Number</i>	To be Assigned
	<i>Filing Date</i>	Herewith
	<i>First Named Inventor</i>	David William End
	<i>Group Art Unit</i>	To Be Assigned
	<i>Examiner Name</i>	To Be Assigned
	<i>Attorney Docket Number</i>	JAB-1680-Div 3

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁸
			Office ³	Number ⁴	KindCode ⁵		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner 's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		PCT International Search Report dated 09/23/1998 for PCT Appln. No. PCT/EP 98/03182.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Page 1 of 1

Attorney Docket Number

JAB-1680-Div 3

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--